Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cardiology (Mahwah, N.J.) Vol. 40; no. 3; pp. 138 - 148
Main Authors:	Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Format:	Journal Article
Language:	English
Published:	New York Wiley Periodicals, Inc 01.03.2017 John Wiley & Sons, Inc
Subjects:	Cardiovascular Diseases - drug therapy Cardiovascular Diseases - epidemiology Clinical trials Dose-Response Relationship, Drug Double-Blind Method Eicosapentaenoic Acid - administration & dosage Eicosapentaenoic Acid - analogs & derivatives Female Follow-Up Studies France - epidemiology General clinical cardiology/adult Health risk assessment Heart attacks Humans Incidence Lipidology Low density lipoprotein Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Prospective Studies Quebec - epidemiology Risk Factors Time Factors Treatment Outcome Trial Designs Triglycerides United Kingdom - epidemiology United States - epidemiology Clinical trials General clinical cardiology/adult Lipidology
ISSN:	0160-9289, 1932-8737, 1932-8737
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!